April 26th 2024
During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed the intracranial efficacy of brigatinib from the ALTA-1L trial for patients with ALK+ non–small cell lung cancer in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Updates from PAPILLON: 1L Amivantamab + Chemotherapy in Advanced NSCLC
November 14th 2023Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Alexander Spira, MD, PhD, FACP, to review data from PAPILLON, which combined amivantamab and chemotherapy as frontline treatment for patients with advanced NSCLC.
Watch
Tailoring Approaches Beyond Steroids for irAEs in Cancer Treatment
November 11th 2023For many immune-related adverse events, steroids are used as frontline treatment. However, it remains unclear if steroids allow for preservation of the antitumor immune response, resulting in the need for more options for patients with cancer.
Read More
Porter Explores Data for Sotorasib in KRAS-Mutated NSCLC
November 2nd 2023During a Targeted Oncology™ Community Case Forum event in collaboration with the Tennessee Oncology Practice Society, Jason Porter, MD, reviewed the CodeBreaK 100 and CodeBreaK 200 trials of sotorasib for patients with KRAS-mutant non–small cell lung cancer.
Read More
Mohamed Discusses Newer Chemoimmunotherapy Regimens in Squamous NSCLC
October 31st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Mohamed K. Mohamed, MD, PhD, and participants discussed cemiplimab plus chemotherapy and tremelimumab/durvalumab plus chemotherapy as regimens for a patient with metastatic squamous non–small cell lung cancer.
Read More
EGFR Exon 20-Insertion NSCLC Population Sees PFS Benefit from Amivantamab/Chemotherapy
October 21st 2023Combining amivantamab, carboplatin, and pemetrexed in patients with non–small cell lung cancer and an EGFR exon 20 insertion led to improved progression-free survival, overall response rate, duration of response, and a trend toward overall survival benefit vs chemotherapy alone in the randomized phase 3 PAPILLON study.
Read More
Selpercatinib Improves Survival vs Chemotherapy in RET+ NSCLC
October 21st 2023Results phase 3 LIBRETTO-431 trial presented at the 2023 ESMO Congress showed selpercatinib monotherapy demonstrated better survival results than chemotherapy with or without pembrolizumab for patients with RET fusion–positive non–small cell lung cancer.
Read More
In ALK+ NSCLC Alectinib Reduces Disease Risks in Early-Stage Setting
October 21st 2023Results from the phase 3 ALINA trial showed the benefit of ALK inhibition for patients with ALK-positive, early-stage, non–small-cell lung cancer with use of adjuvant alectinib significantly improving disease-free survival.
Read More
Addition of Adjuvant Nivolumab Improves EFS in NSCLC
October 21st 2023In the first phase 3 perioperative study of patients with resectable non–small cell lung cancer given adjuvant nivolumab after surgery and a prior regimen of nivolumab and chemotherapy showed improved event-free survival results.
Read More
Managing Adverse Events in EGFR Exon 20 Insertion–Targeted Therapies for NSCLC
October 20th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Millie S. Das, MD, and participants discussed considerations for managing toxicities of amivantamab and mobocertinib for patients with EGFR exon 20 insertion–positive non–small cell lung cancer.
Read More
Riess Reviews Pivotal Trials for Nonmetastatic Lung Cancer
October 19th 2023During a Targeted Oncology™ Clinical Case Forum event in partnership with the Nevada Oncology Society, Jonathan Riess, MD, MS, summarized the outcomes and impact of the PACIFIC and ADAURA trials in patients with nonmetastatic non–small cell lung cancer.
Read More
Nivolumab/Chemotherapy Regimen Shows EFS Benefits in NSCLC
October 18th 2023Neoadjuvant nivolumab and chemotherapy followed by surgery and adjuvant nivolumab demonstrated improvements in event-free survival, pathologic complete response, and major pathologic response in non–small cell lung cancer.
Read More
Behind the FDA Approval of Neoadjuvant/Adjuvant Pembrolizumab in NSCLC
October 17th 2023In an interview with Targeted Oncology, Heather Wakelee, MD, discussed what community oncologists should know about the newly approved combination of pembrolizumab with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of pembrolizumab monotherapy as post-surgical adjuvant treatment.
Read More